-

06:36:43 AM

PRAX Stock News

PRAX - Praxis Precision Medicines Inc

05/23/22 9:00 AM

Nasdaq : PRAX

management

Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance,

RHEA-AI

very positive

05/11/22 9:00 AM

Nasdaq : PRAX

conferences

Praxis Precision Medicines to Present at Upcoming Investor Conferences

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance,

RHEA-AI

neutral

05/09/22 4:01 PM

Nasdaq : PRAX

clinical trial

Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by statistically significant difference in the placebo-controlled randomized withdrawal phase PRAX-944

RHEA-AI

neutral

05/09/22 4:01 PM

Nasdaq : PRAX

earnings

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results expected in June 2022 Epilepsy Day showcases largest targeted epilepsy portfolio in industry Cash and

RHEA-AI

positive

05/04/22 9:00 AM

Nasdaq : PRAX

conferences

Praxis Precision Medicines to Present at BofA Securities 2022 Healthcare Conference

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance,

RHEA-AI

neutral

05/02/22 4:15 PM

Nasdaq : PRAX

earnings

Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May 9, 2022

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance,

RHEA-AI

neutral

04/27/22 8:25 AM

Nasdaq : PRAX

Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS)

RHEA-AI

very positive

04/13/22 8:00 AM

Nasdaq : PRAX

conferences

Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition

RHEA-AI

neutral

04/01/22 9:00 AM

Nasdaq : PRAX

conferences

Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition

RHEA-AI

negative

03/21/22 9:00 AM

Nasdaq : PRAX

conferences

Praxis Precision Medicines to Present at Stifel’s 4th Annual CNS Day

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition

RHEA-AI

neutral

PRAX Data

IndustryPharmaceutical Preparation Manufacturing
Websitepraxismedicines.com
Security namePraxis Precision Medicines Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Pharmaceuticals: Major

About Praxis Precision Medicines Inc

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.